🟢 Outlook Therapeutics is trading 5.5% up today with no newly reported company-specific catalyst identified

Outlook Therapeutics is trading 5.5% up at $0.71, with no newly reported company-specific catalyst identified for September 16, 2026.

• Latest releases were the September 11 H.C. Wainwright fireside chat and September 10 CEO Connect discussion.
• The FDA approval announcement dates to July 24.
• Positive Nasdaq sentiment supports the move, though biotech is declining; the gain remains largely unexplained and may reflect stock-specific trading activity.